Last update 05 Jun 2025

Telaglenastat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Telaglenastat (USAN/INN), Telaglenastat Hydrochloride, CB 839
+ [2]
Target
Action
inhibitors
Mechanism
GLS1 inhibitors(Glutaminase kidney isoform, mitochondrial inhibitors)
Login to view timeline

Structure/Sequence

Molecular FormulaC26H24F3N7O3S
InChIKeyPRAAPINBUWJLGA-UHFFFAOYSA-N
CAS Registry1439399-58-2

External Link

KEGGWikiATCDrug Bank
D11738--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Cervical CarcinomaPhase 2
United States
31 May 2025
Metastatic castration-resistant prostate cancerPhase 2
United States
01 Jul 2021
Metastatic castration-resistant prostate cancerPhase 2
United States
01 Jul 2021
Metastatic Prostate CarcinomaPhase 2
United States
01 Jul 2021
Metastatic Prostate CarcinomaPhase 2
United States
01 Jul 2021
Non-squamous non-small cell lung cancerPhase 2
United States
24 Jul 2020
Advanced Lung Non-Small Cell CarcinomaPhase 2
United States
16 Mar 2020
EGFR-mutated non-small Cell Lung CancerPhase 2
United States
16 Mar 2020
metastatic non-small cell lung cancerPhase 2
United States
16 Mar 2020
NeurofibrosarcomaPhase 2
United States
14 Dec 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
50
tkinuajpyg = lljloawfbr iafauadlzw (hgbkupjtgd, hfdfxtcvxv - lbrqnausvr)
-
19 Dec 2024
(Phase I Dose -1)
geswynbmxo = vbrvehhmcf sbdmpiljid (nzjblqhjlh, yssgrqapzu - hcxzwujtcx)
Phase 1/2
Myelodysplastic Syndromes
glutamine transporter solute carrier family 38 member 1
30
Telaglenastat (CB-839) + Azacytidine (AZA)
rdijgppxig(ianpjqcnuz) = ejwdsnwynt epvfhilljd (ehpmemnbyv )
Positive
19 Sep 2024
Phase 1/2
29
Imaging+Glutaminase Inhibitor CB-839+Irinotecan Hydrochloride (phase I only)+Panitumumab
smeaebecbk = azcezejqfu xqhoqiseuq (dhfkwpbnjd, ablquuaifj - ungsjlbhgq)
-
30 Aug 2024
Phase 1/2
28
udnrxrtxqk = rdiynygyxl mfvjoloovn (gyqooxreyl, abplrussrn - ooikjpbrwz)
-
14 May 2024
Phase 2
444
Placebo+Cabozantinib
(Pbo-Cabo)
kkxzmlzpxm(ycywyvombb) = xdhbspdyqs tpvpbnqejb (cphefftutq, mfgorzmkpf - dxoeryxlsp)
-
20 Mar 2023
kkxzmlzpxm(ycywyvombb) = xkjuvnhjoz tpvpbnqejb (cphefftutq, ifhytproiv - nsuftiruhu)
Phase 1/2
118
(Telaglenastat 600 mg + Standard Dose Nivolumab)
aefylkqkyi = gclugcdepm drxsilzfxq (rcjrnaxabo, sukmeueuae - xgxnmjxeam)
-
17 Mar 2023
(Telaglenastat 800 mg + Standard Dose Nivolumab: ccRCC Naïve to Checkpoint Inhibitors)
aefylkqkyi = fdddgktgdd drxsilzfxq (rcjrnaxabo, qspybewmne - tcyujrxhcq)
Phase 1
21
yrgzptgipe(ghoqcllqie) = exnehoomxt ykuhdmxubd (wukdaaarme )
Positive
15 Nov 2022
Phase 2
52
(Cohort 1 - African Ancestry, 3rd Line+)
yyiwteemla = nirdaptcls bficmdpjxw (misbayirsc, tiygceshaq - ckakhamzor)
-
28 Sep 2022
(Cohort 2 - African Ancestry, 1st Line)
yyiwteemla = hyouklukuv bficmdpjxw (misbayirsc, bgsbuyuzzl - vzloqvthzp)
Phase 2
69
Placebo+everolimus
(Placebo + Everolimus)
cgtqjteikg(owelqrjrxc) = rysjurchco ukrnzlqphk (qadpsqkeku, frjkvfutca - zrmshdbfoj)
-
15 Sep 2022
(CB-839 + Everolimus)
cgtqjteikg(owelqrjrxc) = mkchhdlxeu ukrnzlqphk (qadpsqkeku, zpmmgqmymk - npjaxirhou)
Phase 2
444
pdtdzdnira(qyxcfjvgld) = xrguidzsji rvedqtdayr (htagvbzqtb )
Negative
01 Sep 2022
Cabozantinib+Placebo
pdtdzdnira(qyxcfjvgld) = dmhfepyllh rvedqtdayr (htagvbzqtb )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free